Any feedback?
Please rate this page
(enzyme.php)
(0/150)

BRENDA support

BRENDA Home
show all | hide all No of entries

Information on EC 2.7.11.30 - receptor protein serine/threonine kinase and Organism(s) Homo sapiens

for references in articles please use BRENDA:EC2.7.11.30
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
EC Tree
IUBMB Comments
The transforming growth factor beta (TGF-beta) family of cytokines regulates cell proliferation, differentiation, recognition and death. Signalling occurs by the binding of ligand to the type II receptor, which is the constitutively active kinase. Bound TGF-beta is then recognized by receptor I, which is phosphorylated and can propagate the signal to downstream substrates [1,3].
Specify your search results
Select one or more organisms in this record: ?
This record set is specific for:
Homo sapiens
Show additional data
Do not include text mining results
Include (text mining) results
Include results (AMENDA + additional results, but less precise)
Word Map
The taxonomic range for the selected organisms is: Homo sapiens
The enzyme appears in selected viruses and cellular organisms
Synonyms
ripk1, bmpr2, ripk3, tgf-beta receptor, tbetarii, alk-1, acvrl1, bmpr-ii, bmprii, tbetar-ii, more
SYNONYM
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
activin receptor-like kinase 1
activin receptor-like kinase 1 gene
-
activin receptor-like kinase 5
activin receptor-like kinase 7
activin receptor-like kinase-7
-
-
activin-like kinase receptor 1
-
-
activin-like kinase receptor 4
-
-
ALK4
-
-
BMPR-II
-
-
bone morphogenetic protein receptor II gene
-
bone morphogenetic protein type II receptor
-
-
ESK2
-
-
-
-
MIS type II receptor
-
-
-
-
MISRII
-
-
-
-
MRII
-
-
-
-
receptor interacting serine/threonine kinase 2
-
Serine/threonine-protein kinase receptor R1
-
-
-
-
Serine/threonine-protein kinase receptor R4
-
-
-
-
Serine/threonine-protein kinase receptor R5
-
-
-
-
Serine/threonine-protein kinase receptor R6
-
-
-
-
SKR1
-
-
-
-
SKR2
-
-
-
-
SKR3
-
-
-
-
SKR4
-
-
-
-
SKR5
-
-
-
-
SKR6
-
-
-
-
TbetaKI
-
-
TbetaR-I
-
-
TbetaRI
-
-
TbetaRI kinase
-
TbetaRI receptor kinase
-
TBRI kinase
-
TGF-beta receptor
-
-
TGF-beta receptor 1
-
TGF-beta receptor I
-
-
TGF-beta receptor I kinase
TGF-beta receptor II kinase
-
-
TGF-beta receptor kinase
-
-
TGF-beta type I receptor
TGF-beta type I receptor kinase
-
-
TGF-beta type I receptor serine/threonine kinase
-
TGF-beta type II receptor
-
-
-
-
TGF-beta type-I receptor
-
-
TGFbetaRI/II kinase
-
-
transforming growth factor beta type-I receptor
-
-
transforming growth factor-beta receptor
-
-
transforming growth factor-beta receptor 1
-
transforming growth factor-beta receptor I
-
-
transforming growth factor-beta type 1 receptor kinase
-
-
transforming growth factor-beta type I receptor
-
-
transforming growth factor-beta type I receptor kinase
-
-
TRKI
-
-
TSK-7L
-
-
-
-
type I receptor kinase
-
-
type I receptor TGF-beta kinase
-
-
additional information
-
ALK7 is a type I serine/threonine kinase receptor belonging to the TGF-beta family of proteins
REACTION TYPE
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
Phosphorylation
-
-
SYSTEMATIC NAME
IUBMB Comments
ATP:[receptor-protein] phosphotransferase
The transforming growth factor beta (TGF-beta) family of cytokines regulates cell proliferation, differentiation, recognition and death. Signalling occurs by the binding of ligand to the type II receptor, which is the constitutively active kinase. Bound TGF-beta is then recognized by receptor I, which is phosphorylated and can propagate the signal to downstream substrates [1,3].
CAS REGISTRY NUMBER
COMMENTARY hide
146702-86-5
-
152060-53-2
-
154907-75-2
-
SUBSTRATE
PRODUCT                       
REACTION DIAGRAM
ORGANISM
UNIPROT
COMMENTARY
(Substrate) hide
LITERATURE
(Substrate)
COMMENTARY
(Product) hide
LITERATURE
(Product)
Reversibility
r=reversible
ir=irreversible
?=not specified
ATP + KKVLTQMGSPSIRCS(P)SV(P)S
ADP + ?
show the reaction diagram
-
Smad3-derived peptide substrate
-
-
?
ATP + KKVLTQMGSPSIRCS(P)SVA
ADP + ?
show the reaction diagram
-
Smad3-derived peptide substrate
-
-
?
ATP + KKVLTQMGSPSIRCS(P)SVS
ADP + ?
show the reaction diagram
-
Smad3-derived peptide substrate
-
-
?
ATP + KMGSPSVRCS(P)SMS
ADP + ?
show the reaction diagram
TGF-beta-induced phosphorylation by TbetaRI receptor kinase of the Smad2-derived, phosphorylated peptide substrate containing Ser465 phosphorylation site, poor activity with nonphosphorylated peptide substrate
-
-
?
ATP + KVLTQMGSPSIRCS(P)SVS
ADP + ?
show the reaction diagram
-
Smad3-derived peptide substrate
-
-
?
ATP + KVLTQMGSPSIRCSSV(P)S
ADP + ?
show the reaction diagram
-
Smad3-derived peptide substrate
-
-
?
ATP + KVLTQMGSPSVRCS(P)SMS
ADP + ?
show the reaction diagram
-
Smad2-derived peptide substrate
-
-
?
ATP + KVLTQMGSPSVRCSSMS
ADP + ?
show the reaction diagram
-
Smad2-derived peptide substrate
-
-
?
ATP + KVLTQMGSPSVRCSSMS(P)S
ADP + ?
show the reaction diagram
-
Smad2-derived peptide substrate
-
-
?
ATP + Smad
ADP + phosphorylated Smad
show the reaction diagram
ATP + Smad2
ADP + phosphorylated Smad2
show the reaction diagram
ATP + Smad3
ADP + phosphorylated Smad3
show the reaction diagram
ATP + [actividin receptor]
ADP + [actividin receptor] phosphate
show the reaction diagram
ATP + [TGF-beta receptor II]
ADP + [TGF-beta receptor II] phosphate
show the reaction diagram
ATP + [TGF-beta receptor I]
ADP + [TGF-beta receptor I] phosphate
show the reaction diagram
additional information
?
-
NATURAL SUBSTRATE
NATURAL PRODUCT
REACTION DIAGRAM
ORGANISM
UNIPROT
COMMENTARY
(Substrate) hide
LITERATURE
(Substrate)
COMMENTARY
(Product) hide
LITERATURE
(Product)
REVERSIBILITY
r=reversible
ir=irreversible
?=not specified
ATP + Smad
ADP + phosphorylated Smad
show the reaction diagram
-
involved in ALK5 activation of p38 MAPK signaling and of GADDbeta45 and BGN expression induced by TGF-beta
-
-
?
ATP + Smad2
ADP + phosphorylated Smad2
show the reaction diagram
ATP + Smad3
ADP + phosphorylated Smad3
show the reaction diagram
ATP + [actividin receptor]
ADP + [actividin receptor] phosphate
show the reaction diagram
ATP + [TGF-beta receptor II]
ADP + [TGF-beta receptor II] phosphate
show the reaction diagram
-
regulation and metabolism, overview
-
-
?
ATP + [TGF-beta receptor I]
ADP + [TGF-beta receptor I] phosphate
show the reaction diagram
additional information
?
-
COFACTOR
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
METALS and IONS
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
INHIBITOR
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
(1'R,5'S,6'S)-2-(3',5'-dibromo-1',6'-dihydroxy-4'-oxocyclohex-2'-enyl) acetonitrile
the small dibromotyrosine derivative purified from Pseudoceratina sp. suppresses TGF-beta responsiveness by inhibiting TGF-beta type I receptor serine/threonine kinase activity. The compound inhibits the TGF-beta-stimulated transcriptional activations of 3TP-Lux and decreases phosphorylated Smad2/3 levels and the nuclear translocation of Smad2/3 increased by TGF-beta. The compound inhibits TGF-beta-induced EMT and wound healing of A-549 cells and is a potential therapeutic agent for fibrotic disease and cancer treatment. The compound has no effects on TGF-beta receptor synthesis but attenuates TGF-beta-induced transcriptional activation in Mv1Lu cells and TGF-beta-induced expression of fibronectin and PAI-1 in A549 and NMuMG cells and TGF-beta-induced cell migration
4(quinolin-4-yl)-substituted 5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole derivatives
-
IC50 of 0.00005-0.0013 mM
4-phenyl substituted pyrazole inhibitors
-
inhibitory potency of 4-phenyl substituted pyrazole derivatives, IC50 of 30-555 nM, overview
-
4-phenyl-substituted 5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole derivatives
-
IC50 of 0.000005-0.0195 mM
calphostin C
-
-
LY-2157299
LY-2157299 inhibits TGF-beta mediated SMAD2 activation and hematopoietic suppression in primary hematopoietic stem cells. In vivo administration of LY-2157299 ameliorates anemia in a TGF-beta overexpressing transgenic mouse model of bone marrow failure. Treatment with LY-2157199 stimulates hematopoiesis from primary myelodysplastic syndrome bone marrow specimens
LY2109761
-
TGF-beta receptor kinase inhibitor LY2109761 reverses the anti-apoptotic effects of TGF-beta1 in myelo-monocytic leukaemic cells, it LY2109761 enhanced apoptosis only in the presence of exogenously added TGF-beta1
LY2157299
-
inhibits Smad3 and Smad3 phosphorylation and antagonizes TGF-beta receptor I kinase activity in vivo in human cancer cells implanted into nude mice, pharmacokinetic model, overview
LY364947
LY566578
-
competitive to ATP, noncompetitive to the peptide substrate, IC50 is 70 nM, mechanism
LY580276
-
competitive to ATP, noncompetitive to the peptide substrate, IC50 is 580 nM, mechanism
PD98059
-
-
PEG10
-
ancient retroviral/retrotransposon element intergrated as a single copy gene in to human chromosome 7q21, encodes two splicing varaiants PEG10-RF1 and PEG10-RF1/2, gag- and gag-pol-like proteins that interact with TGF-beta family proteins, DNA and amino acid sequence deteramination and analysis of PEG10-RF1, PEG10-RF1 inhibits ALK1 and ALK5 signaling by direct interaction, overview
Rapamycin
-
-
SB-431542
-
specific TGF-beta receptor kinase inhibitor, a potent antitumor agent for human cancers, induces anchorage-independent cell growth in TGF-beta growth-inhibited cells, and colony formation in growth-induced cells, overview
SB203580
-
-
SD-208
additional information
-
ACTIVATING COMPOUND
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
actividin
-
actividin A
-
required for activity in a complex formed with ALK4 and ActRIIB or ActRII, identification of the functional binding site
-
actividin B
-
required for activity in a complex formed with ALK4 and ActRIIB or ActRII, identification of the functional binding site
-
SARA protein
i.e. Smad anchor for receptor activation protein, binding site for co-modulator Smad4, modulates self-association of partially phosphorylated Smad2 preventing premature release of monophosphorylated substrate, interaction with Smad2 via the Smad2 MH2 domain
-
TGF-beta
-
TGF-beta 3
-
binds and activates ALK5
-
KM VALUE [mM]
SUBSTRATE
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
0.0057 - 0.0088
ATP
0.26
KKVLTQMGSPSIRCS(P)SVS
-
pH 7.5, 30°C, recombinant wild-type ALK5
0.331
KVLTQMGSPSVRCS(P)SMS
-
pH 7.5, 30°C, recombinant wild-type ALK5
Ki VALUE [mM]
INHIBITOR
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
0.000028
LY364947
-
pH 7.5, 30°C, recombinant mutant T204D ALK5, inhibition of autophosphorylation
0.000038
LY566578
-
pH 7.5, 30°C, recombinant mutant T204D ALK5, inhibition of autophosphorylation
0.000037
LY580276
-
pH 7.5, 30°C, recombinant mutant T204D ALK5, inhibition of autophosphorylation
IC50 VALUE [mM]
INHIBITOR
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
0.00005 - 0.0013
4(quinolin-4-yl)-substituted 5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole derivatives
Homo sapiens
-
IC50 of 0.00005-0.0013 mM
0.00003 - 0.000555
4-phenyl substituted pyrazole inhibitors
Homo sapiens
-
inhibitory potency of 4-phenyl substituted pyrazole derivatives, IC50 of 30-555 nM, overview
-
0.000005 - 0.0195
4-phenyl-substituted 5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole derivatives
Homo sapiens
-
IC50 of 0.000005-0.0195 mM
0.000051 - 0.000175
LY364947
0.00007
LY566578
Homo sapiens
-
competitive to ATP, noncompetitive to the peptide substrate, IC50 is 70 nM, mechanism
0.00058
LY580276
Homo sapiens
-
competitive to ATP, noncompetitive to the peptide substrate, IC50 is 580 nM, mechanism
pH OPTIMUM
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
TEMPERATURE OPTIMUM
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
22 - 30
assay at
25
-
assay at
30
-
assay at
ORGANISM
COMMENTARY hide
LITERATURE
UNIPROT
SEQUENCE DB
SOURCE
SOURCE TISSUE
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
SOURCE
from patients of German origin with tentative diagnosis of hereditary hemorrhagic telangiectasia
Manually annotated by BRENDA team
-
ALK3
Manually annotated by BRENDA team
-
anaplastic carcinoma lung cell
Manually annotated by BRENDA team
low ALK7 expression level
Manually annotated by BRENDA team
-
hepatoma cell line
Manually annotated by BRENDA team
-
a myeloid leukemic cell line
Manually annotated by BRENDA team
-
pancreatic Smad4 null cell line, expression of Smad2 and Smad3
Manually annotated by BRENDA team
-
an ovarian surface epithelial cell line
Manually annotated by BRENDA team
-
an ovarian surface epithelial cell line
Manually annotated by BRENDA team
-
a myeloid leukemic cell line
Manually annotated by BRENDA team
high ALK7 expression level
Manually annotated by BRENDA team
-
breast carcinoma cell line, derived from malignant pleural effusions
Manually annotated by BRENDA team
-
breast carcinoma cell line, derived from malignant pleural effusions
Manually annotated by BRENDA team
-
breast Smad4 null cell line, expression of Smad2 and Smad3
Manually annotated by BRENDA team
-
osteosarcoma cell line
Manually annotated by BRENDA team
-
a myelo-monocytic leukemic cell line
Manually annotated by BRENDA team
-
carcinoma breast cell
Manually annotated by BRENDA team
-
an ovarian cancer cell line
Manually annotated by BRENDA team
-
and beta cell lines
Manually annotated by BRENDA team
-
a myelo-monocytic leukemic cell line
Manually annotated by BRENDA team
-
a myelo-monocytic leukemic cell line
Manually annotated by BRENDA team
-
diverse VACO cell lines, Smad4 null cell lines, expression analysis of Smad2, overview
Manually annotated by BRENDA team
LOCALIZATION
ORGANISM
UNIPROT
COMMENTARY hide
GeneOntology No.
LITERATURE
SOURCE
GENERAL INFORMATION
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
malfunction
physiological function
SMAD7 is a negative regulator of TGF-beta receptor I (TBRI) kinase. The enzyme increases Smad7 via increased TGF-beta signaling
UNIPROT
ENTRY NAME
ORGANISM
NO. OF AA
NO. OF TRANSM. HELICES
MOLECULAR WEIGHT[Da]
SOURCE
SEQUENCE
LOCALIZATION PREDICTION?
AMHR2_HUMAN
573
1
62750
Swiss-Prot
Secretory Pathway (Reliability: 2)
AVR2B_HUMAN
512
1
57724
Swiss-Prot
Secretory Pathway (Reliability: 1)
BMPR2_HUMAN
1038
1
115201
Swiss-Prot
Secretory Pathway (Reliability: 2)
BMR1A_HUMAN
532
1
60198
Swiss-Prot
Secretory Pathway (Reliability: 2)
BMR1B_HUMAN
502
1
56930
Swiss-Prot
other Location (Reliability: 2)
TGFR2_HUMAN
567
1
64568
Swiss-Prot
Secretory Pathway (Reliability: 4)
AVR2A_HUMAN
513
1
57848
Swiss-Prot
Secretory Pathway (Reliability: 1)
TGFR1_HUMAN
503
2
55960
Swiss-Prot
Secretory Pathway (Reliability: 1)
ACV1B_HUMAN
505
1
56807
Swiss-Prot
Secretory Pathway (Reliability: 1)
ACV1C_HUMAN
493
1
54871
Swiss-Prot
Secretory Pathway (Reliability: 1)
ACVL1_HUMAN
503
1
56124
Swiss-Prot
Secretory Pathway (Reliability: 2)
ACVR1_HUMAN
509
1
57153
Swiss-Prot
Secretory Pathway (Reliability: 2)
A0A0B5HR54_HUMAN
509
1
57169
TrEMBL
Secretory Pathway (Reliability: 2)
B5BUG9_HUMAN
532
1
60171
TrEMBL
Secretory Pathway (Reliability: 2)
A0A804HJQ0_HUMAN
507
1
56983
TrEMBL
Secretory Pathway (Reliability: 2)
A0A0S2Z539_HUMAN
334
1
38170
TrEMBL
Secretory Pathway (Reliability: 4)
H3BTZ2_HUMAN
163
0
18497
TrEMBL
Secretory Pathway (Reliability: 5)
A8KAE3_HUMAN
502
1
56828
TrEMBL
other Location (Reliability: 2)
F8VXZ5_HUMAN
114
0
13113
TrEMBL
other Location (Reliability: 2)
Q4VAU9_HUMAN
303
0
34222
TrEMBL
other Location (Reliability: 2)
A0A0S2Z310_HUMAN
503
1
56124
TrEMBL
Secretory Pathway (Reliability: 2)
A0A0S2Z2Y3_HUMAN
351
1
39449
TrEMBL
Secretory Pathway (Reliability: 2)
Q59FL1_HUMAN
514
1
58206
TrEMBL
other Location (Reliability: 5)
E7EN07_HUMAN
329
0
37222
TrEMBL
Secretory Pathway (Reliability: 2)
G3V1W8_HUMAN
517
1
57504
TrEMBL
Secretory Pathway (Reliability: 1)
W8DXU8_HUMAN
461
1
52744
TrEMBL
Secretory Pathway (Reliability: 4)
F8W1R9_HUMAN
383
2
41849
TrEMBL
Secretory Pathway (Reliability: 1)
A0A8A3P3K3_HUMAN
266
1
30275
TrEMBL
Secretory Pathway (Reliability: 2)
B4DY26_HUMAN
434
1
48875
TrEMBL
other Location (Reliability: 3)
A8K8R5_HUMAN
1038
1
115191
TrEMBL
Secretory Pathway (Reliability: 2)
B4DUF0_HUMAN
240
0
27277
TrEMBL
other Location (Reliability: 4)
Q5T7S2_HUMAN
503
2
55960
TrEMBL
Secretory Pathway (Reliability: 1)
Q53SF4_HUMAN
153
0
17701
TrEMBL
other Location (Reliability: 5)
W8DYI2_HUMAN
319
1
36257
TrEMBL
Secretory Pathway (Reliability: 4)
D2JYI1_HUMAN
592
1
67457
TrEMBL
Secretory Pathway (Reliability: 4)
W8DY43_HUMAN
353
1
40385
TrEMBL
Secretory Pathway (Reliability: 4)
A3QNQ0_HUMAN
567
1
64568
TrEMBL
Secretory Pathway (Reliability: 4)
D3DPA4_HUMAN
509
1
57153
TrEMBL
Secretory Pathway (Reliability: 2)
A0A0S2Z4H5_HUMAN
359
1
41059
TrEMBL
Secretory Pathway (Reliability: 4)
B4E0D4_HUMAN
329
0
37162
TrEMBL
Secretory Pathway (Reliability: 2)
B4E2S6_HUMAN
397
1
45018
TrEMBL
other Location (Reliability: 3)
Q53SV1_HUMAN
355
1
39412
TrEMBL
Secretory Pathway (Reliability: 2)
A0A804HHZ2_HUMAN
436
1
48339
TrEMBL
Secretory Pathway (Reliability: 2)
H3BPI9_HUMAN
172
0
19170
TrEMBL
other Location (Reliability: 4)
B4DXN7_HUMAN
465
2
51871
TrEMBL
Secretory Pathway (Reliability: 1)
B4DPT9_HUMAN
150
0
17285
TrEMBL
other Location (Reliability: 2)
A0A0S2Z345_HUMAN
443
1
49642
TrEMBL
Secretory Pathway (Reliability: 2)
A0A0S2Z2Y4_HUMAN
399
0
45201
TrEMBL
Secretory Pathway (Reliability: 2)
RIPK2_HUMAN
540
0
61195
Swiss-Prot
-
PDB
SCOP
CATH
UNIPROT
ORGANISM
MOLECULAR WEIGHT
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
65000
-
ALK1 protein, determined by SDS-PAGE
SUBUNIT
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
additional information
POSTTRANSLATIONAL MODIFICATION
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
phosphoprotein
-
ALK5 performs autophosphorylation, wild-type and mutant T204D enzymes
PROTEIN VARIANTS
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
A78G
-
site-directed mutagenesis, the mutation affects binding of actividin
D89A
-
site-directed mutagenesis, the mutation does not affect binding of actividin
E74A
-
site-directed mutagenesis, the mutation affects binding of actividin
E88A
-
site-directed mutagenesis, the mutation does not affect binding of actividin
F82A
-
site-directed mutagenesis, the mutation slightly affects binding of actividin
G79A
-
site-directed mutagenesis, the mutation affects binding of actividin
H312Q
naturally occuring mutation in Japanese pulmonary arterial hypertension patients
I70A
-
site-directed mutagenesis, the mutation of a residue from the ALK4 extracellular domain affects the binding of activin and the substantial effects of the dominant negative truncated ALK4 mutant
K222R
-
inactive mutant
K72A
-
site-directed mutagenesis, the mutation does not affect binding of actividin
K80A
-
site-directed mutagenesis, the mutation affects binding of actividin
L381P
naturally occuring mutation in Japanese pulmonary arterial hypertension patients
L40A
-
site-directed mutagenesis, the mutation of a residue from the ALK4 extracellular domain affects the binding of activin and the substantial effects of the dominant negative truncated ALK4 mutant
L75A
-
site-directed mutagenesis, the mutation of a residue from the ALK4 extracellular domain affects the binding of activin and the substantial effects of the dominant negative truncated ALK4 mutant
L85A
-
site-directed mutagenesis, the mutation affects binding of actividin
L90A
-
site-directed mutagenesis, the mutation does not affect binding of actividin
M53A
-
site-directed mutagenesis, the mutation slightly affects binding of actividin
P71A
-
site-directed mutagenesis, the mutation affects binding of actividin
P77A
-
site-directed mutagenesis, the mutation of a residue from the ALK4 extracellular domain affects the binding of activin and the substantial effects of the dominant negative truncated ALK4 mutant
P81A
-
site-directed mutagenesis, the mutation does not affect binding of actividin
Q201D
-
constitutively active ALK1 mutant
R479Q
naturally occuring mutation in Japanese pulmonary arterial hypertension patients
R484Q
naturally occuring mutation in Japanese pulmonary arterial hypertension patients
R91A
-
site-directed mutagenesis, the mutation affects binding of actividin
S38A
-
site-directed mutagenesis, the mutation slightly affects binding of actividin
S55A
-
site-directed mutagenesis, the mutation affects binding of actividin
S86A
-
site-directed mutagenesis, the mutation affects binding of actividin
S87A
-
site-directed mutagenesis, the mutation affects binding of actividin
T194D
T202D
site-directed mutagenesis
T204D
-
constitutively active ALK5 mutant
T93A
-
site-directed mutagenesis, the mutation affects binding of actividin
V73A
-
site-directed mutagenesis, the mutation of a residue from the ALK4 extracellular domain affects the binding of activin and the substantial effects of the dominant negative truncated ALK4 mutant
V76A
-
site-directed mutagenesis, the mutation affects binding of actividin
Y83A
-
site-directed mutagenesis, the mutation affects binding of actividin
additional information
PURIFICATION (Commentary)
ORGANISM
UNIPROT
LITERATURE
recombinant His-tagged transforming growth factor-beta type I receptor kinase domain mutant T204D from insect Sf9 cells by nickel affinity chromatography
-
recombinant His-tagged wild-type and mutant ALK5 from Spodoptera frugiperda Sf9 cells by nickel affinity chromatography
-
CLONED (Commentary)
ORGANISM
UNIPROT
LITERATURE
activin receptor-like kinase 1 gene, ALK1 is located on chromosome 12q13, DNA and amino acid sequence determination of wild-type and mutant enzymes, genotyping
ALK7, DNA and amino acid sequence determination and analysis, genetic organization, determination of several isoforms by alternative splicing of ALK7
co-expression and co-localization of ALK1 mutant Q201D and cytoplasmic PEG10-RF1 mutant YFP in COS-1 cells, expression of ALK1 and ALK5 with PEG10-RF1 in a two-hydrid system in Saccharomyces cerevisiae, overview
-
expression of HA-tagged wild-type ALK7 in rat FaO hepatoma cells and transiently of HA-tagged ALK mutant T194D in human Hep3B hepatoma cells using the adenovirus infection method, expression leads in both cases to an apoptosis-positive phenotype, expression of inactive ALK7 mutant K222R dos not cause an altered phenotype
-
expression of His-tagged transforming growth factor-beta type I receptor kinase domain mutant T204D in Spodoptera frugiperda Sf9 cells using the baculovirus infection system
-
expression of His-tagged wild-type and mutant ALK5 in Spodoptera frugiperda Sf9 cells using the baculovirus infection system
-
functional co-expression of TGF-beta and the soluble intracellular domain of the TGF-beta type I receptor in murine mammary gland epithelial cells and in mink lung epithelial cells inducing growth inhibition
-
gene ALK5, transient recombinant expression of FLAG-tagged enzyme mutant T202D in HEKT293 cells
surface expression of wild-type and mutant ALK4 type I receptors in HEK293T cells, expression of wild-type and mutant ALK4 type I receptors in mink lung epithelial cells, Mv1Lu cells
-
transient expression of wild-type and mutant enzymes in COS-7 cells, and in Min-6 and Hep-G2 cells
-
EXPRESSION
ORGANISM
UNIPROT
LITERATURE
(1'R,5'S,6'S)-2-(3',5'-dibromo-1',6'-dihydroxy-4'-oxocyclohex-2'-enyl) acetonitrile has no effects on TGF-beta receptor synthesis
down-regulation of ALK1 in LX-2 cells by the herbal compound Cpd861, cells are treated with TGF-beta1 (5 ng/ml) Cpd861 (0.1 mg/ml), TGF-beta1 (5 ng/ml) plus Cpd861 (an extract of 10 herbs traditionally applied as chinese medicine, 5 ng/ml) for 24 h to investigate the effect of Cpd861 on the TGF-beta1/ALK1 pathway
-
reduction of endogenous ALK1 expression significantly attenuates BMP9-mediated phosphorylation of Smad1/5 and Smad2
-
the ALK1 gene is constitutively expressed in LX-2 cells and TGF-beta1 does not further increase its expression
-
APPLICATION
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
diagnostics
next to the Curaçao criteria, genetic analysis contributes as an essential tool to a reliable diagnosis of clinically affected hereditary hemorrhagic telangiectasia patients and clinically unsymptomatic hereditary hemorrhagic telangiectasia patients, thus helping to take early preventive measures even before the occurrence of first clinical symptoms, the PCR-SSP technique can facilitate this high task of genetic analysis in routine hereditary hemorrhagic telangiectasia diagnostics and underlines the importance of using molecular diagnosis for early identification of individuals carrying mutations and being at risk of vascular complications
medicine
pharmacology
enzyme inhibitor (1'R,5'S,6'S)-2-(3',5'-dibromo-1',6'-dihydroxy-4'-oxocyclohex-2'-enyl) acetonitrile is a potential therapeutic agent for fibrotic disease and cancer treatment
REF.
AUTHORS
TITLE
JOURNAL
VOL.
PAGES
YEAR
ORGANISM (UNIPROT)
PUBMED ID
SOURCE
Ge, R.; Rajeev, V.; Subramanian, G.; Reiss, K.A.; Liu, D.; Higgins, L.; Joly, A.; Dugar, S.; Chakravarty, J.; Henson, M.; McEnroe, G.; Schreiner, G.; Reiss, M.
Selective inhibitors of type I receptor kinase block cellular transforming growth factor-beta signaling
Biochem. Pharmacol.
68
41-50
2004
Homo sapiens
Manually annotated by BRENDA team
Ottesen, J.J.; Huse, M.; Sekedat, M.D.; Muir, T.W.
Semisynthesis of phosphovariants of Smad2 reveals a substrate preference of the activated TbetaRI kinase
Biochemistry
43
5698-5706
2004
Homo sapiens (P36897), Homo sapiens
Manually annotated by BRENDA team
Peng, S.B.; Yan, L.; Xia, X.; Watkins, S.A.; Brooks, H.B.; Beight, D.; Herron, D.K.; Jones, M.L.; Lampe, J.W.; McMillen, W.T.; Mort, N.; Sawyer, J.S.; Yingling, J.M.
Kinetic characterization of novel pyrazole TGF-beta receptor I kinase inhibitors and their blockade of the epithelial-mesenchymal transition
Biochemistry
44
2293-2304
2005
Homo sapiens
Manually annotated by BRENDA team
Roberts, H.J.; Hu, S.; Qiu, Q.; Leung, P.C.; Caniggia, I.; Gruslin, A.; Tsang, B.; Peng, C.
Identification of novel isoforms of activin receptor-like kinase 7 (ALK7) generated by alternative splicing and expression of ALK7 and its ligand, Nodal, in human placenta
Biol. Reprod.
68
1719-1726
2003
Homo sapiens (Q8NER5), Homo sapiens
Manually annotated by BRENDA team
Sawyer, J.S.; Beight, D.W.; Britt, K.S.; Anderson, B.D.; Campbell, R.M.; Goodson, T.Jr.; Herron, D.K.; Li, H.Y.; McMillen, W.T.; Mort, N.; Parsons, S.; Smith, E.C.; Wagner, J.R.; Yan, L.; Zhang, F.; Yingling, J.M.
Synthesis and activity of new aryl- and heteroaryl-substituted 5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole inhibitors of the transforming growth factor-beta type I receptor kinase domain
Bioorg. Med. Chem. Lett.
14
3581-3584
2004
Homo sapiens, Mus musculus
Manually annotated by BRENDA team
Harrison, C.A.; Gray, P.C.; Koerber, S.C.; Fischer, W.; Vale, W.
Identification of a functional binding site for activin on the type I receptor ALK4
J. Biol. Chem.
278
21129-21135
2003
Homo sapiens
Manually annotated by BRENDA team
Kim, B.C.; van Gelder, H.; Kim, T.A.; Lee, H.J.; Baik, K.G.; Chun, H.H.; Lee, D.A.; Choi, K.S.; Kim, S.J.
Activin receptor-like kinase-7 induces apoptosis through activation of MAPKs in a Smad3-dependent mechanism in hepatoma cells
J. Biol. Chem.
279
28458-28465
2004
Homo sapiens
Manually annotated by BRENDA team
Ungefroren, H.; Groth, S.; Ruhnke, M.; Kalthoff, H.; Fandrich, F.
Transforming growth factor-beta (TGF-beta) type I receptor/ALK5-dependent activation of the GADD45beta gene mediates the induction of biglycan expression by TGF-beta
J. Biol. Chem.
280
2644-2652
2005
Homo sapiens
Manually annotated by BRENDA team
Lux, A.; Beil, C.; Majety, M.; Barron, S.; Gallione, C.J.; Kuhn, H.M.; Berg, J.N.; Kioschis, P.; Marchuk, D.A.; Hafner, M.
Human retroviral gag- and gag-pol-like proteins interact with the transforming growth factor-beta receptor activin receptor-like kinase 1
J. Biol. Chem.
280
8482-8493
2005
Homo sapiens
Manually annotated by BRENDA team
Halder, S.K.; Beauchamp, R.D.; Datta, P.K.
A specific inhibitor of TGF-beta receptor kinase, SB-431542, as a potent antitumor agent for human cancers
Neoplasia
7
509-521
2005
Homo sapiens
Manually annotated by BRENDA team
Fink, S.P.; Mikkola, D.; Willson, J.K.V.; Markowitz, S.
TGF-beta-induced nuclear localization of Smad2 and Smad3 in Smad4 null cancer cell lines
Oncogene
22
1317-1323
2003
Homo sapiens
Manually annotated by BRENDA team
Watanabe, R.; Shen, Z.P.; Tsuda, K.; Yamada, Y.
Insulin gene is a target in activin receptor-like kinase 7 signaling pathway in pancreatic beta-cells
Biochem. Biophys. Res. Commun.
377
867-872
2008
Homo sapiens
Manually annotated by BRENDA team
Zhou, L.; Nguyen, A.N.; Sohal, D.; Ying Ma, J.; Pahanish, P.; Gundabolu, K.; Hayman, J.; Chubak, A.; Mo, Y.; Bhagat, T.D.; Das, B.; Kapoun, A.M.; Navas, T.A.; Parmar, S.; Kambhampati, S.; Pellagatti, A.; Braunchweig, I.; Zhang, Y.; Wickrema, A.; Medicherla, S.; Boultwood, J.; Platanias, L.C.; Higgins, L.S.
Inhibition of the TGF-beta receptor I kinase promotes hematopoiesis in MDS
Blood
112
3434-3443
2008
Homo sapiens (P36897)
Manually annotated by BRENDA team
Xu, Y.; Tabe, Y.; Jin, L.; Watt, J.; McQueen, T.; Ohsaka, A.; Andreeff, M.; Konopleva, M.
TGF-beta receptor kinase inhibitor LY2109761 reverses the anti-apoptotic effects of TGF-beta1 in myelo-monocytic leukaemic cells co-cultured with stromal cells
Br. J. Haematol.
142
192-201
2008
Homo sapiens
Manually annotated by BRENDA team
Fujiwara, M.; Yagi, H.; Matsuoka, R.; Akimoto, K.; Furutani, M.; Imamura, S.; Uehara, R.; Nakayama, T.; Takao, A.; Nakazawa, M.; Saji, T.
Implications of mutations of activin receptor-like kinase 1 gene (ALK1) in addition to bone morphogenetic protein receptor II gene (BMPR2) in children with pulmonary arterial hypertension
Circ. J.
72
127-133
2008
Homo sapiens (P37023), Homo sapiens
Manually annotated by BRENDA team
Bueno, L.; de Alwis, D.P.; Pitou, C.; Yingling, J.; Lahn, M.; Glatt, S.; Troconiz, I.F.
Semi-mechanistic modelling of the tumour growth inhibitory effects of LY2157299, a new type I receptor TGF-beta kinase antagonist, in mice
Eur. J. Cancer
44
142-150
2008
Homo sapiens
Manually annotated by BRENDA team
Zhao, S.; Ammanamanchi, S.; Brattain, M.; Cao, L.; Thangasamy, A.; Wang, J.; Freeman, J.W.
Smad4-dependent TGF-beta signaling suppresses RON receptor tyrosine kinase-dependent motility and invasion of pancreatic cancer cells
J. Biol. Chem.
283
11293-11301
2008
Homo sapiens
Manually annotated by BRENDA team
Xu, G.; Bernaudo, S.; Fu, G.; Lee, D.Y.; Yang, B.B.; Peng, C.
Cyclin G2 is degraded through the ubiquitin-proteasome pathway and mediates the antiproliferative effect of activin receptor-like kinase 7
Mol. Biol. Cell
19
4968-4979
2008
Homo sapiens
Manually annotated by BRENDA team
Haneen, S.; Johanna, H.; Ulrich, G.; Jens, S.S.; Frank, R.; Karl, H.; Peter, B.
Mutation analysis of "Endoglin" and "Activin receptor-like kinase" genes in German patients with hereditary hemorrhagic telangiectasia and the value of rapid genotyping using an allele-specific PCR-technique
BMC Med. Genet.
10
53
2009
Homo sapiens (P37023), Homo sapiens
Manually annotated by BRENDA team
Upton, P.D.; Davies, R.J.; Trembath, R.C.; Morrell, N.W.
Bone morphogenetic protein (BMP) and activin type II receptors balance BMP9 signals mediated by activin receptor-like kinase-1 in human pulmonary artery endothelial cells
J. Biol. Chem.
284
15794-15804
2009
Homo sapiens
Manually annotated by BRENDA team
Li, L.; Zhao, X.Y.; Wang, B.E.
Down-regulation of transforming growth factor beta 1/activin receptor-like kinase 1 pathway gene expression by herbal compound 861 is related to deactivation of LX-2 cells
World J. Gastroenterol.
14
2894-2899
2008
Homo sapiens
Manually annotated by BRENDA team
Zhou, L.; McMahon, C.; Bhagat, T.; Alencar, C.; Yu, Y.; Fazzari, M.; Sohal, D.; Heuck, C.; Gundabolu, K.; Ng, C.; Mo, Y.; Shen, W.; Wickrema, A.; Kong, G.; Friedman, E.; Sokol, L.; Mantzaris, I.; Mantzaris, G.; Pellagatti, A.; Boultwood, J.; Platanias, L.C.; Steidl, U.; Yan, L.; Yingling, J.M.; Lahn, M.M.
Reduced SMAD7 leads to overactivation of TGF-beta signaling in MDS that can be reversed by a specific inhibitor of TGF-beta receptor I kinase
Cancer Res.
71
955-963
2011
Homo sapiens (P36897)
Manually annotated by BRENDA team
Chen, C.L.; Kao, Y.C.; Yang, P.H.; Sung, P.J.; Wen, Z.H.; Chen, J.J.; Huang, Y.B.; Chen, P.Y.
A small dibromotyrosine derivative purified from Pseudoceratina sp. suppresses TGF-beta responsiveness by inhibiting TGF-beta type I receptor serine/threonine kinase activity
J. Cell. Biochem.
117
2800-2814
2016
Homo sapiens (P36897)
Manually annotated by BRENDA team
Ota, M.; Tahara, T.; Otsuka, T.; Jing, W.; Nomura, T.; Hayashi, R.; Shimasaki, T.; Nakamura, M.; Shibata, T.; Arisawa, T.
Association between receptor interacting serine/threonine kinase 2 polymorphisms and gastric cancer susceptibility
Oncol. Lett.
15
3772-3778
2018
Homo sapiens (O43353)
Manually annotated by BRENDA team